iBio (NYSEMKT:IBIO) Shares Down 3.6%

iBio, Inc. (NYSEMKT:IBIO)’s share price traded down 3.6% during mid-day trading on Wednesday . The stock traded as low as $1.81 and last traded at $1.88. 269,653 shares traded hands during mid-day trading, an increase of 138% from the average session volume of 113,212 shares. The stock had previously closed at $1.95.

iBio Price Performance

The business’s 50-day moving average price is $1.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.

Institutional Investors Weigh In On iBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IBIO. HighTower Advisors LLC acquired a new position in shares of iBio in the 1st quarter valued at approximately $25,000. US Bancorp DE increased its stake in shares of iBio by 178.4% in the first quarter. US Bancorp DE now owns 67,100 shares of the company’s stock worth $29,000 after buying an additional 43,000 shares during the last quarter. Virtu Financial LLC raised its holdings in iBio by 182.4% in the second quarter. Virtu Financial LLC now owns 121,828 shares of the company’s stock valued at $32,000 after acquiring an additional 78,692 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in iBio during the 4th quarter valued at $33,000. Finally, Goldman Sachs Group Inc. grew its stake in iBio by 127.6% in the second quarter. Goldman Sachs Group Inc. now owns 293,743 shares of the company’s stock worth $78,000 after purchasing an additional 164,664 shares in the last quarter. Hedge funds and other institutional investors own 7.90% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.